
Surgical Science Q2 2023 - Short-term challenges – unchanged long-term prospects

Redeye updates its estimates following Surgical Science's Q2 2023 report, which featured a 'mixed bag'. We judge that notable positives from the report include c30% y/y Industry/OEM sales growth and EBITDA/EBIT aligning with our expectations. Notable negatives include net sales coming in c5% below our expectations due to c8% lower-than-expected Educational Products sales. We finetune our estimates and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Surgical Science Q2 2023 - Short-term challenges – unchanged long-term prospects](#)